Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
AstraZeneca
Colorcon
McKinsey
Baxter

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Litigation Details for MYLAN PHARMACEUTICALS INC. v. JANSSEN PHARMACEUTICALS, INC. (E.D. Pa. 2015)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

MYLAN PHARMACEUTICALS INC. v. JANSSEN PHARMACEUTICALS, INC. (E.D. Pa. 2015)

Docket   Start Trial Date Filed 2015-05-29
Court District Court, E.D. Pennsylvania Date Terminated 2015-10-16
Cause 28:2201 Declaratory Judgement (Insurance) Assigned To Mark A. Kearney
Jury Demand None Referred To Marilyn Heffley
Parties JANSSEN PHARMACEUTICALS, INC.; MYLAN PHARMACEUTICALS INC.
Patents 8,163,798; 8,629,179
Attorneys ANIL H. PATEL; CEDRIC C.Y. TAN; DAVID T. PRITIKIN; JAMES A. HIGH , JR.; LAURA A. LANGE; MEGHAN M. RACHFORD; MICHAEL L. BINNS; PETER S. sCHOI; RUBEN H. MUNOZ-PASCUA; TIMOTHY H. KRATZ
Firms McGuire Woods LLP; McGuirewoods LLP; Sidley Austin LLP; Sidley, Austin
Link to Docket External link to docket
Small Molecule Drugs cited in MYLAN PHARMACEUTICALS INC. v. JANSSEN PHARMACEUTICALS, INC.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for MYLAN PHARMACEUTICALS INC. v. JANSSEN PHARMACEUTICALS, INC. (E.D. Pa. 2015)

Date Filed Document No. Description Snippet Link To Document
2015-07-30 36 Mylan regarding a separate patent, U.S. Patent No. 8,163,798 (“the ’798 patent). Janssen is wrong and cites…considered on a patent-by-patent basis.4 There is a separate first filer for each patent listed in the…fact that the ’179 patent will expire on the same day as the ’798 patent, the patent at issue in the West…invalidity or non-infringement of U.S. Patent No. 8,629,179 (“the ’179 patent”) was a compulsory counterclaim…one patent is ever compulsory in an infringement action based on a separately issued U.S. patent. Moreover External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Boehringer Ingelheim
McKesson
Express Scripts
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.